In December, 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, Hubei province, China, and COVID-19 has become a threat to global public health.[@bib1]

Use of corticosteroid-based therapy to reduce inflammatory-induced lung injury has been described for patients with severe COVID-19,[@bib2], [@bib3] similar to the use of corticosteroids to treat severe acute respiratory syndrome (SARS) during the SARS outbreak in 2003.[@bib4] However, improper use of systemic corticosteroids can increase the risk of osteonecrosis of the femoral head (ONFH).

In a retrospective study of 539 patients with SARS who received corticosteroid therapy,[@bib5] the incidence of steroid-induced ONFH was 24%, and increased incidence of steroid-induced ONFH was associated with total corticosteroid dose and the use of more than one type of corticosteroid. Improper or delayed treatment of steroid-induced ONFH can cause hip pain, claudication, and even disability of the lower limbs.

Overall, we call for caution in the use of corticosteroids for COVID-19 and do not recommend this as a routine treatment. To prevent steroidinduced ONFH, corticosteroids should be considered only for patients undergoing septic shock, or in critical cases.[@bib6], [@bib7] Corticosteroids should be minimised in dose and duration, and the use of multiple types should be avoided. We believe that bisphosphonates and vitamin E should be prescribed to patients who are undergoing corticosteroid treatment; anticoagulants, vasodilators, and traditional Chinese medicine could also be considered.[@bib8], [@bib9], [@bib10] Close follow-up should be conducted after discharged, with MRI as the best option for early detection of ONFH. Physical therapy and combined pharmacotherapy have been recommended for patients with early-stage steroid-induced ONFH.[@bib11]
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